NRx Pharmaceuticals (NASDAQ:NRXP) Given New $45.00 Price Target at Ascendiant Capital Markets

NRx Pharmaceuticals (NASDAQ:NRXP) had its price target hoisted by Ascendiant Capital Markets from $44.00 to $45.00 in a research report released on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other equities research analysts also recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $19.00 price objective on shares of NRx Pharmaceuticals in a report on Monday, November 25th. EF Hutton Acquisition Co. I upgraded shares of NRx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 21st.

NRx Pharmaceuticals Trading Up 3.1 %

NASDAQ NRXP opened at $1.35 on Monday. The stock’s 50 day moving average is $1.36 and its two-hundred day moving average is $2.10. The company has a market capitalization of $16.33 million, a price-to-earnings ratio of -0.61 and a beta of 1.27. NRx Pharmaceuticals has a 1-year low of $1.10 and a 1-year high of $7.33.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NRx Pharmaceuticals stock. Anson Funds Management LP acquired a new position in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 142,525 shares of the company’s stock, valued at approximately $241,000. Anson Funds Management LP owned about 1.33% of NRx Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.